Advertisement

Clinical Journal of Gastroenterology

, Volume 12, Issue 6, pp 592–597 | Cite as

Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report

  • Atsushi Naganuma
  • Ken SatoEmail author
  • Toru Fukuchi
  • Masashi Namikawa
  • Satoru Kakizaki
  • Toshio Uraoka
  • Hiroshi Ohnishi
  • Hiroaki Okamoto
Case Report
  • 95 Downloads

Abstract

Direct-acting antiviral agent (DAA)-based therapies have been the 1st choice of antiviral agents for chronic hepatitis C throughout the world. The treatment period of DAA-based therapy has been greatly shortened by the improvement of their efficiency. Thus, glecaprevir (GLE)/pibrentasvir (PIB) therapy has enabled the therapeutic period to be reduced from 12 to 8 weeks in cases of genotype 1 or 2 chronic hepatitis C without liver cirrhosis. Currently, there is no established rescue therapy for patients who experience treatment failure on GLE/PIB therapy; however, some patients have been rescued by other regimens, including sofosbuvir (SOF)/velpatasvir (VEL) plus ribavirin (RBV) therapy and GLE/PIB, SOF, and RBV therapy. We experienced the case of a DAA-naïve non-cirrhotic patient with genotype 2a who showed virologic relapse at post-treatment week 13 following 8-week GLE/PIB therapy. After we confirmed that he did not have resistance-associated substitutions against GLE or PIB, we tried to rescue the patient using prolonged (12-week) GLE/PIB therapy. Fortunately, a sustained virologic response was achieved without any adverse events. Although this was a single-case report and is assumed to be rare, the same regimen might be effective for treatment failure with 8-week GLE/PIB therapy.

Keywords

Chronic hepatitis C Direct-acting antiviral agents Rescue therapy Treatment failure Treatment period 

Notes

Compliance with ethical standards

Conflict of interest

Sato K received lecture fees from MSD K.K. and AbbVie Inc., and research funding from AbbVie. Kakizaki S received lecture fees from MSD K.K., AbbVie Inc. and Gilead Sciences, Inc., and research funding from BMS K.K. and Gilead Sciences, Inc.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from the patient for being included in the Case report.

References

  1. 1.
    Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557–65.CrossRefGoogle Scholar
  2. 2.
    Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67:505–13.CrossRefGoogle Scholar
  3. 3.
    Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 2018;53:566–75.CrossRefGoogle Scholar
  4. 4.
    Izumi N, Takehara T, Chayama K, et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int. 2018;12:356–67.CrossRefGoogle Scholar
  5. 5.
    Interview form of Maviret® version 5; 2019. p 55. https://a-connect.abbvie.co.jp/-/media/assets/pdf/products/maviret/if_Maviret_j.pdf. Accessed July 2019.
  6. 6.
    Interview form of Maviret® version 5; 2019. p 58. https://a-connect.abbvie.co.jp/-/media/assets/pdf/products/maviret/if_Maviret_j.pdf. Accessed July 2019.
  7. 7.
    Sato K, Uraoka T. Challenge to overcome: nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus. World J Gastroenterol. 2018;24:4304–10.CrossRefGoogle Scholar
  8. 8.
    Akuta N, Sezaki H, Suzuki F, et al. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J Med Virol. 2017;89:1248–54.CrossRefGoogle Scholar
  9. 9.
    Ikeda H, Watanabe T, Shimizu H, et al. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018;48:802–9.CrossRefGoogle Scholar
  10. 10.
    Suda G, Ogawa K, Yamamoto Y, et al. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52:1122–9.CrossRefGoogle Scholar
  11. 11.
    Akuta N, Sezaki H, Suzuki F, et al. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens. J Med Virol. 2019;91:102–6.CrossRefGoogle Scholar
  12. 12.
    Osawa M, Imamura M, Teraoka Y, et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol. 2019;54:291–6.CrossRefGoogle Scholar
  13. 13.
    Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and Pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study. Hepatol Res. 2019;49:617–26.CrossRefGoogle Scholar
  14. 14.
    Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70:1019–23.CrossRefGoogle Scholar
  15. 15.
    Interview form of Maviret® version 5; 2019. p 62. https://a-connect.abbvie.co.jp/-/media/assets/pdf/products/maviret/if_Maviret_j.pdf. Accessed July 2019.
  16. 16.
    Smolders EJ, Willemse SB, El-Sherif O, et al. The observed effect of gastric bypass surgery on direct-acting antiviral treatment: a case report. Ann Hepatol. 2018;17:525–9.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  1. 1.Department of Gastroenterology, Takasaki General Medical CenterNational Hospital OrganizationTakasakiJapan
  2. 2.Department of Internal MedicineKiryu Kosei General HospitalKiryuJapan
  3. 3.Department of Gastroenterology and HepatologyGunma University Graduate School of MedicineMaebashiJapan
  4. 4.Division of Virology, Department of Infection and ImmunityJichi Medical University School of MedicineShimotsukeJapan

Personalised recommendations